背景:远程皮肤病学是通过通信技术进行皮肤病学的实践。这项研究的目的是分析其在头两年在西班牙卫生领域的实施情况。
方法:横断面描述性研究。它包括在连续两年实施非面对面模式后,在萨拉曼卡保健区(西班牙)的皮肤科医生和家庭医生之间进行相互协商。共进行了25,424次咨询(20,912次面对面和4,512次非面对面);通过随机抽样选择了1000次,每种模式的一半。
方法:转诊率,响应时间和解决时间,病理类型,诊断一致性,和咨询质量。
结果:年转诊率为42.9/1000居民(面对面35.3人,非面对面7.6人)。城市地区的面对面转诊率较高(37.1),农村地区的非面对面转诊率较高(10.4)。非面对面咨询的响应时间为2.4±12.7天,面对面咨询的响应时间为56±34.8天(p<0.001)。非面对面咨询的解决率为44%。诊断一致性,通过卡帕指数评估,面对面咨询为0.527,非面对面咨询为0.564。在非出席协商中更加遵守质量标准。
结论:远程皮肤病学似乎是解决皮肤病学问题的有效工具,一个快速的,有效,和更高质量的响应关注皮肤病理。
■ClinicalTrials.gov标识符:NCT05625295。2022年11月21日注册(https://clinicaltrials.gov/ct2/show/NCT05625295)。
BACKGROUND: Teledermatology is the practice of dermatology through communication technologies. The aim of this study is to analyze its implementation in a Spanish health area during its first two years.
METHODS: Cross-sectional descriptive study. It included interconsultations between dermatologists and family physicians in the Salamanca Health Area (Spain) after the implementation of the non-face-to-face modality over a period of two consecutive years. A total of 25,424 consultations were performed (20,912 face-to-face and 4,512 non-face-to-face); 1000 were selected by random sampling, half of each modality.
METHODS: referral rate, response time and resolution time, type of pathology, diagnostic concordance, and quality of consultation.
RESULTS: The annual referral rate was 42.9/1000 inhabitants (35.3 face-to-face and 7.6 non-face- to-face). The rate of face-to-face referrals was higher in urban areas (37.1) and the rate of non- face-to-face referrals in rural areas (10.4). The response time for non-face-to-face consultations was 2.4 ± 12.7 days and 56 ± 34.8 days for face-to-face consultations (p < 0.001). The resolution rate for non-face-to-face consultations was 44%. Diagnostic concordance, assessed by the kappa index, was 0.527 for face-to-face consultations and 0.564 for non-face-to-face consultations. Greater compliance with the quality criteria in the non-attendance consultations.
CONCLUSIONS: Teledermatology appears to be an efficient tool in the resolution of dermatological problems, with a rapid, effective, and higher quality response for attention to skin pathologies.
UNASSIGNED: ClinicalTrials.gov Identifier: NCT05625295. Registered on 21 November 2022 ( https://clinicaltrials.gov/ct2/show/ NCT05625295).